BridgeBio Pharma Inc
BBIOHealthcare|Biotechnology|USA
$85.81
-4.28 (-4.75%)
About
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
Stock Price
+85.5%(1Y)
Pipeline Summary
5 total trials3
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
NOT_YET_RECRUITING: 1Terminated: 3Active: 1
Active Trials (1)
An Observational Study Using Artificial Intelligence (AI) Algorithms on Electrocardiography (ECG), Point-of-care Ultrasound (POCUS), and Transthoracic Echocardiophy (TTE) to Estimate the Under-diagnosis of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Across a Diverse Range of US Health Systems.
NCT07062848Transthyretin (TTR) Amyloid Cardiomyopathy
Active
Enrollment: 1,500,000 participants
BioScore
6.8/10
Buy
Ownership
Recent Insider Trades
Cook Jennifer E.SELL
2026-06-2439,363 shares @ $69.92
Valantine HannahSELL
2026-06-235,004 shares @ $68.25
Cook Jennifer E.SELL
2026-06-1590,240 shares @ $66.62
Kumar NeilSELL
2026-06-0580,000 shares @ $67.67
Kumar NeilSELL
2026-05-2126,103 shares @ $69.44
Recent News
2026-07-09 14:28:09
2026-07-09 11:55:54
2026-06-28 23:25:59
2026-06-23 00:00:04
2026-06-16 13:01:06
Data last updated: Jul 12, 2026, 07:31 PM